Undoubtedly, interest in this therapeutic approach has been renewed with the demonstration that very low doses of the CD19/CD3 BiTE antibody construct, blinatumomab, can eliminate target cells in patients with non-Hodgkin’s lymphomas [22]. The gene discussed is CD19; the disease is non-Hodgkin lymphoma.